RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+1.73%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$6.85B
AUM Growth
+$6.85B
(+3.3%)
Cap. Flow
+$642M
Cap. Flow
% of AUM
9.38%
Top 10 Holdings %
Top 10 Hldgs %
38.32%
Holding
136
New
16
Increased
27
Reduced
15
Closed
12
Top Buys
| 1 |
Ultragenyx Pharmaceutical
RARE
|
$115M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$94.1M |
| 3 |
Penumbra
PEN
|
$67.7M |
| 4 |
argenx
ARGX
|
$62M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
$52.9M |
Top Sells
| 1 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
$153M |
| 2 |
InMode
INMD
|
$19.9M |
| 3 |
IDEAYA Biosciences
IDYA
|
$17.6M |
| 4 |
Guardant Health
GH
|
$11.2M |
| 5 |
AGEN
Agenus
AGEN
|
$10.3M |
Sector Composition
| 1 | Healthcare | 93.33% |
| 2 | Financials | 0.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BNR
126
Burning Rock Biotech
BNR
$85.6M
| – | – |
-3,000
| Closed | -$536K |
|
127
CVRx
CVRX
$204M
| – | – |
-150,000
| Closed | -$2.48M |
|
|
128
InMode
INMD
$917M
| – | – |
-249,998
| Closed | -$19.9M |
|
129
MoonLake Immunotherapeutics
MLTX
$3.78B
| – | – |
-750,000
| Closed | -$7.39M |
|
|
PROF
130
Profound Medical
PROF
$131M
| – | – |
-122,098
| Closed | -$1.79M |
|
131
Scholar Rock
SRRK
$3.3B
| – | – |
-161,612
| Closed | -$5.34M |
|
132
Twist Bioscience
TWST
$1.57B
| – | – |
-18,473
| Closed | -$1.98M |
|
|
AFIB
133
DELISTED
Acutus Medical, Inc. Common Stock
AFIB
| – | – |
-491,834
| Closed | -$4.35M |
|
|
CELL
134
DELISTED
PhenomeX Inc. Common Stock
CELL
| – | – |
-257,546
| Closed | -$5.04M |
|
|
DRNA
135
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| – | – |
-7,582,396
| Closed | -$153M |
|
|
MAAC
136
DELISTED
Montes Archimedes Acquisition Corp. Class A Common Stock
MAAC
| – | – |
-400,000
| Closed | -$3.16M |
|